Journal article
Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection
Future oncology (London, England), v 19(20), pp 1415-1427
01 Jun 2023
PMID: 37218514
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Plain language summaryThis study looked at how people with early-stage non-small-cell lung cancer did after surgery to completely remove the disease. It compared two groups of patients: those whose disease came back after surgery and those whose disease did not come back after surgery. The group of people whose disease came back after surgery did not live as long as those whose disease did not come back after surgery (31.5 months vs 75.6 months). Patients whose disease came back had a lower chance of living at least 5 years after surgery and they had more hospital visits and doctor's office visits. In addition, those whose disease came back within 1 year did not live as long as those whose disease came back between 1 and 5 years after surgery. Preventing or delaying the return of disease after surgery is important for improving the lives of patients with early-stage non-small-cell lung cancer.
Tweetable abstractA real-world study reported that lung cancer recurrence after surgery leads to shorter lifespans and higher healthcare utilization, emphasizing the need for recurrence prevention to improve survival and economic benefits.
Aim: Real-world data on outcomes for early-stage non-small-cell lung cancer (NSCLC) are needed to better understand the benefits of new therapies. Methods: In this retrospective study using the ConcertAI Patient360 (TM) database, overall survival and healthcare resource utilization were compared among patients with recurrent and non-recurrent completely resected stage IB-IIIA NSCLC. Results: Recurrence was associated with a shorter median overall survival compared with non-recurrence (31.5 months vs 75.6 months, respectively), lower survival probability 5-years post-resection, and higher healthcare resource utilization. Patients with late recurrence had a longer restricted mean survival time versus patients with early recurrence. Conclusion: Results from this real-world study highlight the potential value of preventing or delaying recurrence in patients with early-stage NSCLC.
Metrics
Details
- Title
- Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection
- Creators
- Howard West - City of HopeXiaohan Hu - Merck & Co., Inc., Rahway, NJ, USA (United States)Diana Chirovsky - Merck & Co., Inc., Rahway, NJ, USA (United States)Mark S. Walker - Concert Pharmaceuticals (United States)Yuexi Wang - Concert Pharmaceuticals (United States)Alpana Kaushiva - Concert Pharmaceuticals (United States)Jon Tepsick - Concert Pharmaceuticals (United States)Ayman Samkari - MSD (Mexico)
- Publication Details
- Future oncology (London, England), v 19(20), pp 1415-1427
- Publisher
- Future Medicine Ltd
- Number of pages
- 13
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000991448500001
- Scopus ID
- 2-s2.0-85167481179
- Other Identifier
- 991021838139304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Oncology